Kinase drug discovery 20 years after imatinib: progress and future directions
Protein kinases regulate nearly all aspects of cell life, and alterations in their expression, or
mutations in their genes, cause cancer and other diseases. Here, we review the remarkable …
mutations in their genes, cause cancer and other diseases. Here, we review the remarkable …
NTRK fusion-positive cancers and TRK inhibitor therapy
N TRK gene fusions involving either NTRK1, NTRK2 or NTRK3 (encoding the neurotrophin
receptors TRKA, TRKB and TRKC, respectively) are oncogenic drivers of various adult and …
receptors TRKA, TRKB and TRKC, respectively) are oncogenic drivers of various adult and …
Cell death-based treatment of lung adenocarcinoma
TV Denisenko, IN Budkevich, B Zhivotovsky - Cell death & disease, 2018 - nature.com
The most common type of lung cancer is adenocarcinoma (ADC), comprising around 40% of
all lung cancer cases. In spite of achievements in understanding the pathogenesis of this …
all lung cancer cases. In spite of achievements in understanding the pathogenesis of this …
First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
Background The efficacy of the ALK inhibitor crizotinib as compared with standard
chemotherapy as first-line treatment for advanced ALK-positive non–small-cell lung cancer …
chemotherapy as first-line treatment for advanced ALK-positive non–small-cell lung cancer …
A historical overview of protein kinases and their targeted small molecule inhibitors
R Roskoski Jr - Pharmacological research, 2015 - Elsevier
Protein kinases play a predominant regulatory role in nearly every aspect of cell biology and
they can modify the function of a protein in almost every conceivable way. Protein …
they can modify the function of a protein in almost every conceivable way. Protein …
Phase II study of crizotinib in East Asian patients with ROS1-positive advanced non–small-cell lung cancer
Purpose Approximately 1% to 2% of non–small-cell lung cancers (NSCLCs) harbor a c-ros
oncogene 1 (ROS1) rearrangement. Crizotinib, an inhibitor of anaplastic lymphoma kinase …
oncogene 1 (ROS1) rearrangement. Crizotinib, an inhibitor of anaplastic lymphoma kinase …
Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non–Small-Cell Lung Cancer and Brain Metastases
Purpose Crizotinib is an oral kinase inhibitor approved for the treatment of ALK-rearranged
non–small-cell lung cancer (NSCLC). The clinical benefits of crizotinib in patients with brain …
non–small-cell lung cancer (NSCLC). The clinical benefits of crizotinib in patients with brain …
[HTML][HTML] The role of the ALK receptor in cancer biology
B Hallberg, RH Palmer - Annals of Oncology, 2016 - Elsevier
ABSTRACT A vast array of oncogenic variants has been identified for anaplastic lymphoma
kinase (ALK). Therefore, there is a need to better understand the role of ALK in cancer …
kinase (ALK). Therefore, there is a need to better understand the role of ALK in cancer …
AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications
C Zhu, Y Wei, X Wei - Molecular cancer, 2019 - Springer
Molecular targeted therapy for cancer has been a research hotspot for decades. AXL is a
member of the TAM family with the high-affinity ligand growth arrest-specific protein 6 …
member of the TAM family with the high-affinity ligand growth arrest-specific protein 6 …
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study
DR Camidge, YJ Bang, EL Kwak, AJ Iafrate… - The lancet …, 2012 - thelancet.com
Background ALK fusion genes occur in a subset of non-small-cell lung cancers (NSCLCs).
We assessed the tolerability and activity of crizotinib in patients with NSCLC who were …
We assessed the tolerability and activity of crizotinib in patients with NSCLC who were …